United Therapeutics Corp. PT Raised to $56.00 at Goldman Sachs Group Inc. (UTHR)
Goldman Sachs Group Inc. upped their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note issued on Wednesday, AnalystRatingsNetwork.com reports. Goldman Sachs Group Inc.’s price objective would indicate a potential downside of 29.39% from the stock’s previous close.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.34% on Wednesday, hitting $79.306. 230,206 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $44.51 and a 1-year high of $79.95. The stock’s 50-day moving average is $73.99 and its 200-day moving average is $67.12. The company has a market cap of $3.959 billion and a price-to-earnings ratio of 13.72.
United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 24.4% on a year-over-year basis. Analysts expect that United Therapeutics Corp. will post $5.99 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. Finally, analysts at Guggenheim raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $61.00 to $69.00 in a research note to investors on Tuesday, July 30th. They now have a “neutral” rating on the stock.
One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the company. United Therapeutics Corp. presently has a consensus rating of “Hold” and a consensus target price of $64.20.
In other United Therapeutics Corp. news, CEO Martine A. Rothblatt sold 3,833 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $76.98, for a total value of $295,064.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.